Protocol Single compound
PT-141
Bremelanotide
Melanocortin receptor agonist referenced in central nervous system research.
Compare side by side →Compared with:PT-141 vs Melanotan II
Laboratory reference · in vitro research data
- Research vial sizes
- 10 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 10 mg | 1 mL | 10 | 1 |
| 10 mg | 2 mL | 5 | 0.5 |
| 10 mg | 3 mL | 3.33 | 0.333 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Syringe
Research dossier · published literature summary
01
Mechanism of action
PT-141 (bremelanotide) is a melanocortin receptor agonist, acting mainly on central MC4 receptors involved in sexual motivation.
02
Observed research endpoints
- RECONNECT (two phase 3 trials, 1,267 premenopausal women with hypoactive sexual desire disorder): significant increases in desire and reductions in related distress vs placebo.
- Integrated safety data (1,247 women): nausea was the main reason for stopping treatment.
03
Regulatory & safety context
- FDA-approved (as Vyleesi) only for hypoactive sexual desire disorder in premenopausal women; research-grade material is not that product.
- Most common adverse events: nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%) and headache (11.3% vs 1.9%). Small, transient blood-pressure increases were seen.
- Focal hyperpigmentation was rare at labelled use but affected more than a third of participants after up to 16 consecutive daily administrations.
04
Citations
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899–908.2019-11Phase 3 randomized controlled trialsRead paper ↗
- Clayton AH, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health. 2022;31(2):171–182.2022-02Integrated safety analysisRead paper ↗
Keep exploring
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
View productView COA
Supplier C
TBDPlaceholder — details coming soon
View productView COA